Navigation Links
Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
Date:1/9/2014

EMERYVILLE, Calif., Jan. 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for MDX-8704.  MDX-8704 is a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release capsules) and donepezil HCl being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.

The milestone payments are for the successful completion of studies that support the planned New Drug Application (NDA) filing with the US Food and Drug Administration (FDA) for MDX-8704 by Forest in the first half of 2014.  These studies are based on a development plan agreed to by Adamas and the FDA prior to its license agreement with Forest.  Leveraging Adamas' know-how and intellectual property, the companies are collaborating on the development of the FDC, for which Forest has exclusive US commercialization rights.  Forest is responsible for all regulatory-related activities.  MDX-8704 is covered by multiple Adamas and Forest patents that extend to 2029.

Pursuant to their license agreement for development and commercialization of MDX-8704, Forest paid Adamas $65 million upfront in November 2012, and these $40 million payments are part of up to $95 million in subsequent development and regulatory approval milestones.  In addition, under the terms of the license agreement, Adamas will receive royalties beginning five years after launch on US net sales of FDC products and any additional memantine products for which Adamas' patents are listed in the FDA's Orange Book.

About Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central nervous system (CNS) disorders by enhancing the pharmacokinetic profiles of approved drugs to create novel treatments for use alone and as components of fixed-dose combination products.  The Company is currently advancing a pipeline of aminoadamantane-based drug candidates for the treatment of Parkinson's disease, Alzheimer's disease, and other CNS disorders.  The Phase 2/3 EASED study investigating ADS-5102 (amantadine HCl ER) for the treatment of levodopa-induced dyskinesia in Parkinson's disease has been completed and met its primary endpoint.  MDX-8704 (memantine HCl ER/donepezil) is a fixed-dose combination product candidate in late-stage investigation for the treatment of dementia associated with Alzheimer's disease.  In November 2012, Adamas entered into an agreement with Forest Laboratories, Inc. for the development and commercialization of MDX-8704 in the United States.  Adamas plans to advance its product candidates through approval and to commercialize approved products in the United States through a specialty CNS sales force.  For more information about Adamas, please visit www.adamaspharma.com.


'/>"/>
SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
2. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
3. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
4. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
7. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
8. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
9. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
10. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
11. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance Group, ... to communities across North Carolina, is launching a charity event in conjunction with ... for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy Network ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Health, as medical director. Dr. Negrette has more than a decade of experience ... has worked closely with individuals fighting addictions, eating disorders, psychotic and manic conditions, ...
(Date:7/24/2017)... ... , ... Engineers at the University of Maryland have invented an entirely new ... energy that the body uses. , In ordinary batteries the electrical energy, or ... of the battery is generated by moving positive ions from one end to the ...
(Date:7/24/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery information community, announces a ... a daily basis. , The new video series will feature board-certified doctors explaining ... practices. , When asked about the new video series, the senior editor of ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... scholarship awards to be awarded annually to and divided between two full-time university ... bringing awareness to Amazonian plant medicine. To apply for the scholarship, students are ...
Breaking Medicine News(10 mins):